Thursday, February 16, 2023 10:32:01 AM
$ABUS patent infringement MRNA /\ patent infringement [ $MRNA just pay the da money]
ABUS
-1.6544%
People pose with syringe with needle in front of displayed Moderna logo
U.S. Justice Department logo is seen at Justice Department headquarters in Washington
1 / 2
U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit
People pose with syringe with needle in front of displayed Moderna logo
Blake Brittain
Wed, February 15, 2023 at 10:02 AM MST
In this article:
MRNA
-2.33%
ABUS
-1.6544%
By Blake Brittain
(Reuters) - The U.S. government should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc, the Department of Justice told a Delaware federal court on Tuesday.
The Justice Department's court filing said the United States should be liable for any infringement of Arbutus Biopharma Corp and Genevant Sciences GmbH's patents that took place under Moderna's contract to provide shots for the government's nationwide vaccination effort.
Moderna made the same argument last year in an unsuccessful bid to win an early dismissal of the lawsuit.
Genevant declined to comment on the filing. Representatives for Moderna, the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services did not immediately respond to requests for comment Wednesday.
Warminster Township, Pennsylvania-based Arbutus and Genevant — a joint venture between Arbutus and Roivant Sciences Ltd — sued Cambridge, Massachusetts-based Moderna last year for royalties on its multi-billion-dollar COVID vaccines.
Both Moderna and Pfizer Inc have been the target of multiple patent lawsuits over their COVID vaccines, including a lawsuit brought by Moderna against Pfizer in August.
Moderna asked the Delaware court to dismiss Arbutus and Genevant's case in May, arguing it could only be brought against the government in the U.S. Court of Federal Claims. It cited a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One.
But U.S. District Judge Mitchell Goldberg said in November that Moderna had not yet shown that the vaccines were made for the government or with its authorization and consent under the law, and that it may have instead been an "incidental beneficiary" of the shots.
The Department of Justice responded Tuesday that Moderna should not be liable based on its contract to provide the vaccines to the government as part of Operation Warp Speed.
It said the government's liability is limited to Moderna's alleged infringing activity that took place under its U.S. contract.
The case is Arbutus Biopharma Corp v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00252.
(Reporting by Blake Brittain in Washington; Editing by David Bario and David Gregorio)
ABUS
-1.6544%
People pose with syringe with needle in front of displayed Moderna logo
U.S. Justice Department logo is seen at Justice Department headquarters in Washington
1 / 2
U.S. backs Moderna, says government should face COVID-19 vaccine lawsuit
People pose with syringe with needle in front of displayed Moderna logo
Blake Brittain
Wed, February 15, 2023 at 10:02 AM MST
In this article:
MRNA
-2.33%
ABUS
-1.6544%
By Blake Brittain
(Reuters) - The U.S. government should face a patent lawsuit over COVID-19 vaccines, not vaccine maker Moderna Inc, the Department of Justice told a Delaware federal court on Tuesday.
The Justice Department's court filing said the United States should be liable for any infringement of Arbutus Biopharma Corp and Genevant Sciences GmbH's patents that took place under Moderna's contract to provide shots for the government's nationwide vaccination effort.
Moderna made the same argument last year in an unsuccessful bid to win an early dismissal of the lawsuit.
Genevant declined to comment on the filing. Representatives for Moderna, the U.S. Food and Drug Administration and the U.S. Department of Health and Human Services did not immediately respond to requests for comment Wednesday.
Warminster Township, Pennsylvania-based Arbutus and Genevant — a joint venture between Arbutus and Roivant Sciences Ltd — sued Cambridge, Massachusetts-based Moderna last year for royalties on its multi-billion-dollar COVID vaccines.
Both Moderna and Pfizer Inc have been the target of multiple patent lawsuits over their COVID vaccines, including a lawsuit brought by Moderna against Pfizer in August.
Moderna asked the Delaware court to dismiss Arbutus and Genevant's case in May, arguing it could only be brought against the government in the U.S. Court of Federal Claims. It cited a law that was previously used to keep patent disputes from interfering with the supply of war materials during World War One.
But U.S. District Judge Mitchell Goldberg said in November that Moderna had not yet shown that the vaccines were made for the government or with its authorization and consent under the law, and that it may have instead been an "incidental beneficiary" of the shots.
The Department of Justice responded Tuesday that Moderna should not be liable based on its contract to provide the vaccines to the government as part of Operation Warp Speed.
It said the government's liability is limited to Moderna's alleged infringing activity that took place under its U.S. contract.
The case is Arbutus Biopharma Corp v. Moderna Inc, U.S. District Court for the District of Delaware, No. 1:22-cv-00252.
(Reporting by Blake Brittain in Washington; Editing by David Bario and David Gregorio)
Recent ABUS News
- Arbutus Shares Jump After FDA Grants Fast Track Status to Hepatitis B Therapy • IH Market News • 04/15/2026 02:09:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/15/2026 11:31:20 AM
- Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B • GlobeNewswire Inc. • 04/15/2026 11:30:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/14/2026 09:05:20 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/14/2026 09:02:17 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 04/13/2026 11:56:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/23/2026 11:31:10 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/23/2026 11:30:44 AM
- Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- Moderna agrees up to $2.25 billion settlement in COVID vaccine patent dispute • IH Market News • 03/04/2026 11:24:49 AM
- Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
- Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna • GlobeNewswire Inc. • 03/03/2026 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/20/2026 09:01:31 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/17/2026 09:21:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2026 09:01:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:21:34 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/03/2026 01:21:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2026 12:41:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2025 01:00:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 12:31:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 12:31:10 PM
- Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/07/2025 12:01:34 PM
- Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025 • GlobeNewswire Inc. • 10/07/2025 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/10/2025 01:00:46 PM
